We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

63 hedge funds and large institutions have $25.4M invested in BioCryst Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 63 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

26% less call options, than puts

Call options by funds: $124K | Put options by funds: $167K

Holders
63
Holders Change
+63
Holders Change %
–
% of All Funds
2.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
63
Increased
–
Reduced
–
Closed
–
Calls
$124K
Puts
$167K
Net Calls
-$43K
Net Calls Change
-$43K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$8.62M +$9.6M +5,563,615 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.5M +$2.78M +1,613,861 New
TC
3
TFS Capital
Pennsylvania
$2.23M +$2.48M +1,437,319 New
TGHSA
4
TPG Group Holdings (SBS) Advisors
Texas
$1.8M +$2M +1,162,269 New
BIT
5
BlackRock Institutional Trust
California
$1.79M +$1.99M +1,154,701 New
VM
6
VHCP Management
New York
$1.57M +$1.75M +1,013,442 New
Northern Trust
7
Northern Trust
Illinois
$767K +$854K +495,047 New
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$504K +$561K +325,300 New
SGAM
9
Smith Group Asset Management
Texas
$468K +$521K +302,196 New
PP
10
Paloma Partners
Connecticut
$355K +$395K +229,064 New
U
11
UBS
Switzerland
$338K +$376K +218,157 New
Goldman Sachs
12
Goldman Sachs
New York
$321K +$357K +206,775 New
Bank of America
13
Bank of America
North Carolina
$281K +$313K +181,245 New
Deutsche Bank
14
Deutsche Bank
Germany
$280K +$313K +181,387 New
Morgan Stanley
15
Morgan Stanley
New York
$278K +$309K +179,327 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$268K +$298K +172,599 New
Barclays
17
Barclays
United Kingdom
$262K +$292K +169,286 New
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$227K +$253K +146,500 New
FSA
19
Franklin Street Advisors
North Carolina
$216K +$240K +139,000 New
BFA
20
BlackRock Fund Advisors
California
$192K +$214K +123,985 New
Connor, Clark & Lunn Investment Management (CC&L)
21
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$183K +$193K +111,800 New
LMF
22
LMR Master Fund
Cayman Islands
$171K +$191K +110,679 New
CCMH
23
Cornerstone Capital Management Holdings
New York
$160K +$177K +102,600 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$131K +$145K +84,193 New
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$115K +$128K +74,450 New
1
2 3

BCRX Hedge Fund Activity: Q2 2013 in Review

63 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2013, worth a combined $25.4M.

Buyers outnumbered sellers: 63 funds opened new BCRX positions and 0 closed out — a net gain of 63 holders — while 0 added to existing stakes and 0 trimmed.

  • 63 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $25.4M of BioCryst Pharmaceuticals stock for Q2 2013.
  • 63 funds opened new BioCryst Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +63 holders.

Based on aggregated 13F filings for Q2 2013.